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Introduction
Anterior fetal neck masses are rarely encountered dur-
ing the second or third trimester of pregnancy. Careful
routine ultrasound screening easily reveals intrauterine
fetal goiters, which usually appear as symmetrical homo-
geneous masses at the anterior of the neck, and are 
relatively easy to observe because of the fetal neck exten-
sion and accompanying polyhydramnios [1]. Primary
congenital hypothyroidism is seen in 1/3,000–1/4,000
deliveries all over the world [2]. Most of these cases
(80%) are due to dysgenesis of the thyroid gland. The
remaining 15% and 5% are due to dyshormonogenesis
and hypothalamo-hypophysial abnormalities, respec-
tively [3]. Congenital hypothyroidism has an incidence
of one in every 4,000 live births and is one of the most
common treatable causes of mental retardation [4].
Fetal hypothyroidism usually goes unrecognized
when there is no maternal history of thyroid disease or
use of antithyroid medication. However, the conse-
quences of both fetal goiter and impaired thyroid
function are serious [5]. Usually, dyshormonogenesis
is responsible for fetal goiter. Blockage of hormone
biosynthesis increases fetal thyroid-stimulating hor-
mone (TSH) levels and this leads to fetal goiter, resulting
in compression of the esophagus and the trachea and
leading to polyhydramnios, hyperextension of the neck,
and dystocia during labor [6]. Mental and motor retar-
dation also have been reported in the later stages of
life in some affected infants [7]. These are all reasons
why the diagnosis of fetal hypothyroidism should be
established at an early stage and appropriate hormone
replacement treatment should be started. Timely hor-
mone replacement therapy prevents neurologic sequelae,
thus national programs are essential.
Especially when fetal goiter is diagnosed in the sec-
ond trimester, amniocentesis to check TSH levels in
the amniotic fluid may be useful to check fetal thyroid
metabolism. However, the gold standard for the diag-
nosis is fetal blood sampling with cordocentesis to
measure fetal TSH, free triiodothyronine (FT3) and
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free thyroxine (FT4) levels [8]. According to these results,
weekly intra-amniotic thyroxine injections (with optional
simultaneous amniodrainage) can be done and fetal
pulmonary maturation can be followed until delivery
at the 37th week or later, as suggested by Grüner et al
[8]. Monitoring therapeutic efficacy is still problematic;
serial cordocentesis is a reliable method, but it carries
unacceptably high fetal risks. Close thyroid function
monitoring by repeated cordocentesis to adjust fetal
treatment does not appear to be essential and may be
substituted by ultrasonographic follow-up to monitor
fetal goiter decrease [9].
Case Report
A 28-year-old primigravida at 36 weeks’ gestation (who
had previously been followed up at secondary prenatal
care centers) was admitted to our tertiary maternal
care center for a regular antenatal visit for the first time.
She did not mention any abnormalities in her preg-
nancy history. She had completely normal physical find-
ings, and laboratory panels revealed normal routine
blood chemistry and urinalysis results. However, routine
ultrasound examination revealed polyhydramnios (amni-
otic fluid index, 21 cm), and a symmetrical, homoge-
neous solid mass of 3.67 × 7.88 cm was identified at
the anterior of the fetal neck. There was also fetal ascites
(Figures 1–3). No additional abnormalities were identi-
fied in the fetus, and maternal thyroid hormone levels
were in the normal range (Table 1).
After a close follow-up of the pregnancy for 2 weeks,
a 3,250-g fetus with Apgar scores of 8 and 10 at 1 and
5 minutes, respectively, was delivered by cesarean sec-
tion at 38 weeks’ gestation. Blood levels of TSH, FT3
and FT4 for the newborn revealed abnormal thyroid
hormone biosynthesis (Table 2). Thyroxine treatment
was started after labor, and the dosing was adjusted
according to the monthly TSH levels. A decrease in the
size of the fetal goiter was noted during follow-up.
Discussion
Congenital hypothyroidism is quite a rare disorder, with
reported prevalences of 1/3,000 and 1/5,000 deliveries
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Figure 1. A symmetrical, homogeneous solid mass at the
anterior of the fetal neck.
Table 1. Maternal thyroid hormone levels
TSH (µU/mL) 1.9 (0.5–4)
FT3 (pmol/L) 5.7 (2.9–8.9)
FT4 (ng/dL) 1.6 (0.75–1.95)
TSH = thyroid-stimulating hormone; FT3 = free triiodothyronine; FT4 = free
thyroxine.
Table 2. Newborn thyroid hormone levels
FT3 (pmol/L) 0.7 (0.9–2.9)
FT4 (ng/dL) 0.2 (0.75–1.5)
TSH (µU/mL) 125 (3.5–10.4)
TSH = thyroid-stimulating hormone; FT3 = free triiodothyronine; FT4 = free
thyroxine.
Figure 2. A solid mass (3.67 × 7.88 cm) at anterior fetal neck.
Figure 3. Fetal ascites and polyhydramnios.
in Europe and the USA, respectively [10]. A differential
diagnosis of teratoma, thyroglossal duct cyst, cystic
hygroma, lymphangioma, hemangioma, branchial cleft
cyst, or other cystic lesion should be kept in mind when
diagnosing an anterior fetal neck mass ultrasono-
graphically [11].
The first in utero treatment of fetal hypothyroidism
by injecting thyroxine into the amniotic fluid was suc-
cessfully conducted in 1980 in a fetus who was exposed
to large doses of propylthiouracil, which was adminis-
tered to the mother who suffered from Graves’ disease
[12]. Since then, 18 cases, excluding the present case,
have been reported in the English literature. Among these
18 cases, seven (42%) had maternal hyperthyroidism,
which was treated with antithyroid drugs such as propyl-
thiouracil. Eleven cases (58%) showed normal maternal
thyroid functions, and the congenital hypothyroidism
of these fetuses may have been due to the dyshormono-
genesis of the thyroid system or to the acquisition of
maternally derived goitrogen [13]. Polyhydramnios was
seen in 10 of 17 cases (59%), in which the amount of
amniotic fluid was documented. In response to in utero
treatment with thyroxine, all cases showed regression of
fetal goiters. No significant maternal or fetal compli-
cations were reported, except one case of fetal growth
restriction, and all the neonates showed normal psy-
chomotor development after birth [13]. Especially in
the fetal goiter cases diagnosed in the second trimester,
maternal thyroid function should be evaluated and any
history of maternal antithyroid therapy should be ques-
tioned. If the maternal thyroid functions are in the nor-
mal range, amniotic fluid sampling for fetal TSH, FT3
and FT4 levels should be done to detect fetal hypothy-
roidism. If fetal hypothyroidism is diagnosed, intra-
amniotic thyroxine injections (200–600 µg/week) are
administered and serial amniocenteses or preferentially
cordocenteses are performed to follow the changes in
the fetal thyroid metabolism [9,14].
This intrauterine treatment prevents the possible pre-
mature rupture of the membranes and preterm delivery
due to polyhydramnios, as well as the possibility of
dystocia in normal labor due to fetal neck hyperexten-
sion. Normal intrauterine growth, especially central ner-
vous system development, is maintained in a euthyroid
metabolic state [15].
In our case, the patient was diagnosed at the 36th
week of her pregnancy, leaving no time for treatment to
have any positive effects on the fetus before delivery.
We, therefore, did not use this mode of diagnosis and
treatment which requires invasive fetal procedures.
Instead, the patient was followed up with frequent ante-
natal visits until the 38th week, and considering the pos-
sible risks of dystocia due to the previously mentioned
reasons, the fetus was then delivered abdominally. In
the postpartum period, the newborn was diagnosed with
thyroid hormone biosynthesis disorder and thyroxine
replacement was started. By diagnosing the condition
antenatally, the possible psychologic trauma to the fam-
ily was minimized, and the delivery was planned with the
neonatology department in our center, also minimizing
the neonatal risks.
In conclusion, even though rare, congenital hypothy-
roidism should be considered in the differential diagnosis
of fetal neck masses encountered during ultrasound
examination. The adverse effects of this condition on
fetal mental and motor development should be kept in
mind, and rapid evaluation, quick diagnosis and imme-
diate treatment should be undertaken.
In summary, a case of fetal goiter diagnosed pre-
natally was reported. Although in utero treatment for
fetal goiter hypothyroidism seems to be effective, it is
imperative to minimize invasive procedures and to
administer the minimum effective dose of thyroxine to
prevent complications.
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